☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

FDA reject rimonabant

The Food and Drugs Administration (FDA) is unlikely to licence rimonabant (Acomplia®) for the treatment of obesity after the advisory panel voted unanimously against recommending approval.

According to a report at PharmaTimes the panel were mainly concerned with psychiatric adverse effects, including suicide and seizures, seen in patients taking the drug. This led them to conclude that the benefits of treatment do not outweigh the risks.

As previously discussed, rimonobant occupies a last line option for treatment of obesity as an adjunct to diet and exercise. Additionally, MTRAC advised that use should be restricted and the DTB concluded that this drug was not a significant advance.

Action: In the light of this growing concern over safety and the lack of comparative efficacy data with existing treatment options it would seem prudent to make maximum use of existing therapies and to restrict use of rimonabant in existing patients only.

Share 'FDA reject rimonabant' on Email Share 'FDA reject rimonabant' on Delicious Share 'FDA reject rimonabant' on Digg Share 'FDA reject rimonabant' on Facebook Share 'FDA reject rimonabant' on reddit Share 'FDA reject rimonabant' on Twitter


One Comments to “FDA reject rimonabant”

  1. [...] a causal link. The WSJ also notes that rimonabant is not licensed in America, as previously reported, although an application is expected in 2009 as a treatment for Type 2 diabetes. Rimonabant is [...]

    Pingback by Prescribing Advice For GPs » WSJ Links Rimonabant To 5 UK Deaths — June 9, 2008 #

Leave a Reply to Prescribing Advice For GPs » WSJ Links Rimonabant To 5 UK Deaths Cancel reply

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.